Expression of metallothionein and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Liang, Gui You ^a   Lu, Sheng Xun ^a   Xu, Gang ^a   Liu, Xing Da ^a   Li, Jian ^a   Zhang, Deng Shen ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer surrounding tissue; Lung cancers; Metallothionein; Nrf2

Indexed keywords

GCLC PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; ISOPROTEIN; METAL TRANSCRIPTION FACTOR 1; METALLOTHIONEIN; METALLOTHIONEIN 1A; METALLOTHIONEIN 1E; METALLOTHIONEIN 1G; METALLOTHIONEIN 4; METALLOTHIONEIN II; METALLOTHIONEIN III; NQO1 PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ARTICLE; CANCER TISSUE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG CANCER; MEDICAL SCHOOL; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA PURIFICATION; SIGNAL TRANSDUCTION;

HUMANS; LUNG NEOPLASMS; METALLOTHIONEIN; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84881491996     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-199     Document Type: Article

References (20)

1. Müller T, Hengstermann A. Nrf2: friend and foe in preventing cigarette smoking-dependent lung disease. Chem Res Toxicol 2012, 25:1805-1824. 10.1021/tx300145n, 22686525.
2. Pi J, Freeman ML, Yamamoto M. Nrf2 in toxicology and pharmacology: the good, the bad and the ugly?. Toxicol Appl Pharmacol 2010, 244:1-3. 10.1016/j.taap.2010.01.005, 2837784, 20079756.
3. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003, 533:201-209. 10.1016/j.mrfmmm.2003.07.013, 14643421.
4. Klaassen CD, Liu J, Choudhuri S. Metallothionein: an intracellular protein to protect against cadmium toxicity. Ann Rev Pharmacol Toxicol 1999, 39:267-294.
5. Jacob ST, Majumder S, Ghoshal K. Suppression of metallothionein-I/II expression and its probable molecular mechanisms. Environ Health Perspect 2002, 110(Suppl 5):827-830. 1241254, 12426140.
6. Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol 2009, 35:477-483.
7. Tao X, Zheng JM, Xu AM, Chen XF, Zhang SH. Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol Res 2007, 37:820-827. 10.1111/j.1872-034X.2007.00113.x, 17517078.
8. Dziegiel P, Jeleń M, Muszczyńska B, Maciejczyk A, Szulc A, Podhorska-Okołów M, Cegielski M, Zabel M. Role of metallothionein expression in non-small cell lung carcinomas. RoczAkad Med Bialymst 2004, 49(Suppl 1):43-45.
9. Zhong S, Fields CR, Su N, Pan YX, Robertson KD. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 2007, 26:2621-2634. 10.1038/sj.onc.1210041, 17043644.
10. Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, Groshen S, Laird PW, Turla S, Koss MN, Pass HI, Laird-Offringa IA. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 2007, 58:220-230. 10.1016/j.lungcan.2007.06.015, 2752414, 17659810.
11. Theocharis S, Karkantaris C, Philipides T, Agapitos E, Gika A, Margeli A, Kittas C, Koutselinis A. Expression of metallothionein in lung carcinoma: correlation with histological type and grade. Histopathology 2002, 40:143-151. 10.1046/j.1365-2559.2002.01325.x, 11952858.
12. Faller WJ, Rafferty M, Hegarty S, Gremel G, Ryan D, Fraga MF, Esteller M, Dervan PA, Gallagher WM. Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Res 2010, 20:392-400.
13. Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, Formelli F, Pilotti S, Pierotti MA, Greco A. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 2008, 88:474-481. 10.1038/labinvest.2008.17, 18332874.
14. Henrique R, Jerónimo C, Hoque MO, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1274-1278. 10.1158/1055-9965.EPI-04-0659, 15894685.
15. Waalkes MP, Diwan BA, Weghorst CM, Ward JM, Rice JM, Cherian MG, Goyer RA. Further evidence of the tumor-suppressive effects of cadmium in the B6C3F1 mouse liver and lung: late stage vulnerability of tumors to cadmium and the role of metallothionein. J Pharmacol Exp Ther 1993, 266:1656-1663.
16. Waalkes MP, Diwan BA, Rehm S, Ward JM, Moussa M, Cherian MG, Goyer RA. Down-regulation of metallothionein expression in human and murine hepatocellular tumors: association with the tumor-necrotizing and antineoplastic effects of cadmium in mice. J Pharmacol Exp Ther 1996, 277:1026-1033.
17. Majumder S, Roy S, Kaffenberger T, Wang B, Costinean S, Frankel W, Bratasz A, Kuppusamy P, Hai T, Ghoshal K, Jacob ST. Loss of metallothionein predisposes mice to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-kappaB target genes. Cancer Res 2010, 70:10265-10276. 10.1158/0008-5472.CAN-10-2839, 3059562, 21159647.
18. Klaassen CD, Reisman SA. Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. Toxicol Appl Pharmacol 2010, 244:57-65. 10.1016/j.taap.2010.01.013, 2860427, 20122946.
19. MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K, Hayes JD. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009, 30:1571-1580. 10.1093/carcin/bgp176, 3656619, 19608619.
20. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008, 58:262-270. 10.1016/j.phrs.2008.09.003, 2652397, 18838122.